Drugs / Biomatrop
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03634514 | Aug → Sep 2018 | — | Ache Laboratorios Farmaceuticos S.A. | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-12-11 | Ache Laboratorios Farmaceuticos S.A. | Biomatrop (somatropina) 4 UI e 16 UI – pó liofilizado para solução injetável ache.com.br ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biomatrop | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03634514 ↗ |
| Known as | Somatropin | “Recombinant Human Somatropin - Biomatrop” NCT03634514 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human growth hormone - Biomatrop” NCT03634514 ↗ |
| Route | Subcutaneous | “4 UI, subcutaneous, single dose” NCT03634514 ↗ |